TRANSCRIPT — 00:00:00
Can a doctor actually write a script for CJC-1295?
Short answer: not in 2026. The longer answer involves three FDA decisions, one halted Phase 2 trial, and one Joe Rogan announcement.
The short version
CJC-1295 is a synthetic version of a hormone the body already makes — growth-hormone-releasing hormone, or GHRH — but engineered to last days instead of minutes. One modification (called DAC) tethers the peptide to a blood protein called albumin, giving it a half-life of roughly six to eight days in people [3]. That means a single dose keeps growth hormone (GH) and a downstream signal called IGF-1 elevated for over a week.
The compound has never been approved by the FDA for any human use [14]. A small Phase 1 study in healthy adults published in 2006 is the only peer-reviewed human trial [2]. A larger Phase 2 trial was halted the same year and its results were never published [8]. As of 2026, compounding pharmacies operating under 503A rules have no clear legal path to fill a CJC-1295 prescription [20].
For the fuller picture — what it does in the body, what people report, and what the regulatory record actually shows — the pages below are where to start. See also what people report about effects and side effects.
What people are asking
The phrase "script CJC-1295" is what someone types after asking a friend out loud whether a doctor can prescribe a particular peptide. It is a small, specific question, and it has a small, specific answer.
CJC-1295 has never been approved by the U.S. Food and Drug Administration for any human indication [14]. The Drugs@FDA database returns no result for the compound. The original sponsor — ConjuChem Biotechnologies — halted its development program in October 2006 after a participant death during a Phase 2 trial in HIV-associated visceral adiposity, and no New Drug Application has been filed by any sponsor since [8][14].
This site reads the regulatory record carefully and reports what it says. It does not prescribe. It does not refer. It does not sell.
Why "prescription" is the wrong frame
A licensed U.S. physician can write a prescription for any compound they judge appropriate. The harder question is what a pharmacy can lawfully dispense in response.
For an FDA-approved drug, the pathway is simple — the manufacturer ships a labeled product, and a pharmacy fills the prescription. For an unapproved compound, the only legal route is compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, and 503A has three statutory criteria. CJC-1295 fails all three: there is no USP/NF monograph, it is not a component of an FDA-approved drug, and it is not on the FDA 503A bulks list [20].
For a brief window — between the 2023 placement of CJC-1295 in interim Category 2 and the September 27, 2024 removal of that placement — the regulatory status was at least under active categorization [16]. As of 2026, even that scaffold is gone: the January 7, 2025 final interim guidance closed the Category 1/2/3 system to new nominations [18].
What the science actually shows
Underneath the regulatory record there is a small, coherent body of pharmacology.
CJC-1295 is a 30-amino-acid analog of growth hormone-releasing hormone (GHRH), built on the first 29 residues of human GHRH with four protective amino acid substitutions and a C-terminal maleimide group that covalently tethers the peptide to circulating serum albumin. The tether is the defining feature — it extends the plasma half-life from minutes (native GHRH) to roughly six to eight days in healthy adults [3].
The only published Phase 1 paper, Teichman et al. 2006, dosed healthy adults at 30, 60, 125, or 250 μg/kg as a single subcutaneous injection and reported a two- to ten-fold elevation in mean plasma growth hormone (GH) for at least six days, with IGF-1 elevated 1.5- to three-fold for nine to eleven days [2][3]. That paper remains the only peer-reviewed Phase 1 trial of CJC-1295 in the endocrinology literature. There is no Phase 3 evidence. There is no completed Phase 2 outcome paper.
How to read this site
This is an editorial project. It summarizes peer-reviewed studies, FDA briefing documents, and the public regulatory record on a single compound.
The research page walks through the published mechanism and the available human and animal data. The dosage page reports the dose ranges that were administered in published research — not as a prescribing guide, but as a literal record of what investigators gave to study animals and Phase 1 volunteers. The effects page draws on the corpus of community-reported signals and the evidence-based safety cautions, both honestly labeled. The FAQ answers the questions that bring most readers here. The references page lists every primary source.
This site is an independent editorial reading of publicly available research. It does not prescribe, refer, manufacture, sell, or distribute any product.